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Abstract
Introduction: Rheumatoid arthritis (RA) is a multi-organ inflammatory disorder associated with high cardiovascular
morbidity and mortality. We sought to assess cardiac involvement using a comprehensive cardiac magnetic
resonance imaging (cMRI) approach and to determine its association with disease characteristics in RA patients
without symptomatic cardiac disease.
Methods: RA patients with no history and/or clinical findings of systemic or pulmonary hypertension, coronary
artery disease, severe valvular heart disease, atrial fibrillation, diabetes mellitus, or echocardiographic abnormalities
underwent contrast-enhanced cMRI on a 1.5T scanner. Adenosine triphosphate was used to assess perfusion
defects due to microvascular impairment or ischemia, and delayed enhanced imaging was obtained for the
assessment of myocardial inflammation/fibrosis. We explored the associations of cMRI abnormalities with RA
disease activity and severity measures.
Results: Eighteen patients (78% female) with a mean age of 57 ± 10 years were studied. Eight patients (45%)
demonstrated a myocardial abnormality. Perfusion defects under pharmacologic stress were seen in two patients
(11%), one of whom had a circumferential subendocardial perfusion defect and one had a non-segmental
subendocardial perfusion defect. Seven patients (39%) were found to have delayed enhancement, only one of
whom also demonstrated a perfusion defect. Mean disease activity score (DAS)28 was significantly higher in the
group with delayed enhancement compared to the group without by an average of 1.32 DAS28 units (4.77 vs. 3.44
units, respectively; P = 0.011). Corresponding trends to statistical significance were noted in systemic inflammatory
markers, with both C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) quantitatively higher in the
group with delayed enhancement. Other RA characteristics, such as disease duration, autoantibody status, and
current treatments were not significantly associated with cardiac involvement.
Conclusions: Myocardial abnormalities, as detected by cMRI, were frequent in RA patients without known cardiac
disease. Abnormal cMRI findings were associated with higher RA disease activity, suggesting a role for
inflammation in the pathogenesis of myocardial involvement in RA.
Introduction
Rheumatoid arthritis (RA) is a multi-organ inflammatory
disorder affecting approximately 1% of the adult general
population. A reduction in life expectancy in RA patients
is primarily due to an increase of cardiovascular events
[1-4] associated with both ischemic heart disease and con-
gestive heart failure [5,6]. Importantly, myocardial disease
is typically clinically silent [7], only manifesting as myocar-
dial dysfunction after an extended preclinical phase. Myo-
cardial dysfunction may arise from a number of distinct
processes, including micro- and macrovascular coronary
ischemia, myocardial inflammation (myocarditis), and/or
myocardial fibrosis [8], any of which may be active in RA.
Histopathologic studies have confirmed an increased
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limited by their source (autopsy) and age (most from the
1950s and 1960s).
Considering these issues, an updated appraisal of myo-
cardial disease is warranted in RA, preferably using a tech-
nique that is non-invasive and can be serially followed
over time for progression, potentially identifying patients
at the greatest risk of cardiac-related morbidity and mor-
tality. Although some non-invasive methods, such as con-
ventional and tissue-doppler echocardiography and single
photon emission CT (SPECT), may reveal functional
abnormalities [12-16], spatial resolution is not sufficiently
accurate to identify the range of potential myocardial
abnormalities in RA. Contrast-enhanced cardiac magnetic
resonance imaging (MRI) is a non-invasive tool for the
diagnosis of ischemic and non-ischemic heart diseases.
Contrast agents diffused to the interstitial space will be
resorbed into the capillary bed and undergo renal excre-
tion. When the myocardial tissue is damaged, the resorp-
tion rate of contrast will be diminished. Specifically,
delayed myocardial enhancement (delayed enhancement:
DE), particularly when there is a delay in contrast washout
within the tissue can indicate myocardial inflammation,
fibrosis or myocardial infarction (MI) [17-20]. Adding
pharmacological stress can identify myocardial perfusion
impairment in various forms of cardiomyopathy as well as
ischemic heart disease. Areas of reduced perfusion within
the myocardium (perfusion defects: PD) when pharmaco-
logic stress is applied indicate vascular impairment. Seg-
mental PDs (that is, corresponding to the distribution
territory of an epicardial coronary artery) suggest macro-
vascular involvement, while diffuse or non-segmental PDs
are highly suggestive of microvascular impairment [21,22].
Combining contrast enhanced MRI with pharmacologic
stress can aid in identifying underlying pathophysiological
features more accurately than each approach alone.
Recently, several investigators have reported on car-
diac MRI for the assessment of myocardial abnormality
in patients with systemic sclerosis [23-25] and systemic
lupus erythematosus [26]; however, only one report of
cardiac MRI has been published in RA [27]. In this case,
cardiac MRI was used successfully to differentiate myo-
carditis from myocardial infarction [27]. We sought to
identify myocardial abnormalities in RA patients using
contrast enhanced cardiac MRI combined with pharma-
cologic stress perfusion. Further, we sought to explore
the associations of RA disease-related characteristics
with cardiac MRI abnormalities.
Materials and methods
Patients
Consecutive female and male patients with RA as
defined by the American Rheumatism Association clas-
sification criteria [28] were recruited from the
outpatient rheumatology clinic at Itabashi Chuo Medical
Center between October 2007 and December 2008.
Exclusion criteria were current or prior treatment with
prednisone, pregnancy, evidence of cardiomegaly on
chest X-ray, symptoms of heart failure, coronary artery
disease (angina and/or electrocardiogram (ECG) signs
of myocardial ischemia), systolic blood pressure < 90 or
> 150 mm Hg, heart rate < 50 or > 130 bpm, pulmon-
ary arterial hypertension (right ventricular systolic pres-
sure > 40 mm Hg determined by echocardiography),
severe valvular heart disease, atrial fibrillation, diabetes
mellitus, hyperlipdemia, dyslipidemia, history of smok-
ing, abnormalities in echocardiography, history of
bronchoconstriction, contraindication to MRI, hypersen-
sivity to gadolinium or adenosine triphoshate, and cur-
rent or past treatment with prostacyclin. Informed
consent was obtained from all patients and the study
was approved by the ethics committee of Itabashi Chuo
Medical Center, Tokyo, Japan.
Covariate assessments
All patients completed questionnaires regarding medical
history, and underwent clinical examination and basic
screening for conventional atherosclerotic disease risk
factors, including cigarette smoking, systolic and diastolic
blood pressure measurement, chest X-ray, a 12-lead ECG
and a standard echocardiogram at study entry. Routine
laboratory assays including serum cholesterol, triglycer-
ides, high-density lipoprotein (HDL), low-density lipopro-
tein (LDL) and fasting blood glucose concentration, were
performed. Information on demographics, smoking, and
family history was collected by questionnaire. Resting
blood pressure was measured three times in the seated
position, and the average of the last two measurements
was used in the analysis. Hypertension was defined
by systolic blood pressure > 140 mmHg, diastolic
blood pressure > 90 mmHg, or antihypertensive medica-
tion use. Diabetes was defined as a fasting serum glu-
cose > 126 mg/dl or use of antidiabetic medications.
Hyperlipidemia was defined by serum cholesterol > 220
mg/dl, serum triglycerides > 150 mg/dl or LDL > 140
mg/dl. Dyslipidemia was defined by HDL > 40 mg/dl
mg/dl. Composite CV risk measures were calculated
using the Framingham hard 10-year CV risk (National
Cholesterol Education Program) [29]. Plain chest radio-
graphs were diagnosed by a single, trained radiologist
blinded to patients’ characteristics. ECGs were analyzed
by a single, trained cardiologist blinded to patients’ char-
acteristics. Cardiac standard echocardiography, including
2D and Doppler echocardiogram, was performed by a
trained technologist and diagnosed by a trained cardiolo-
gist blinded to patient characteristics. The person who
analyzed the echocardiography knew nothing about the
patient’s clinical characteristics.
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RA disease duration was calculated based on self-report
from the time of physician diagnosis. Current and past
use of glucocorticoids and of biologic and nonbiologic
DMARDs was ascertained by interview. The rheumatoid
factor was assessed by ELISA, with seropositivity defined
at or above a level of 20 units/ml. RA activity was calcu-
lated using the Disease Activity Score for 28 joints with
C-reactive protein (CRP) [30]. Anti-cyclic citrullinated
peptide antibody was assessed by ELISA, with seroposi-
tivity defined at or above a level of six units per
milliliter.
MRI Scanning and Interpretation
Patients underwent cine MRI, pharmacological stress
and rest perfusion, and delayed enhancement MRI. All
contrast MR studies were performed with a 1.5T MRI
scanner (Achieva, Philips, The Netherlands). Adenosine
triphosphate was infused using an automated power
injector at a constant rate of 0.16 mg/kg body weight
per minute for five minutes as a pharmacological stress
agent [31,32]. Subsequently, a gadolinium-based contrast
agent (Magnevist, Schering AG, Berlin, Germany) was
injected into the right antecubital vein (0.1 mmol/kg
body weight) during a first-pass perfusion sequence
using a IR balanced Turbo Field Echo sequence (TR 2.8
ms, TE 1.38 ms, FA 45, slice thickness 8 mm, prepara-
tion pulse delay 200 ms), and images in four contiguous
short-axis orientations were acquired at every two heart-
beats. Adenosine triphoshate infusion was stopped after
completion of the sequence. After five minutes of stress
perfusion MRI, rest first-pass perfusion was scanned by
the same sequence and same injection protocol for the
gadolinium contrast agent. After a 10-minute delay,
delayed enhanced images were obtained by using 3D-
Turbo Field Echo sequence (TR 5.1 ms, TE 2.5 ms, FA
15, slice thickness 8 mm).
Images were viewed using VirtualPlace workstation
(AZE, Tokyo, Japan) and independently analyzed by two
radiologists and a cardiologist who were blinded to
clinical information. Myocardial PDs detected during
pharmacologic stress were categorized as segmental or
non-segmental, based on whether they anatomically coin-
cided with the distribution of an epicardial coronary
artery. Myocardial DE lesions were characterized based
on their presence, shape and anatomic location (Figure
1). Image enhancement was not characterized based on
the intensity of enhancement. Table 1 summarizes the
pathophysiologic interpretations used for different possi-
ble combinations of PD and DE lesions [33-35]. Non-
segmental PD under stress with DE indicates microvas-
cular impairment with myocarditis or fibrosis. Non-
segmental PD under stress without DE indicates micro-
vascular impairment without myocarditis and fibrosis.
Segmental PD under stress without DE suggests macro-
vascular impairment without myocarditis and fibrosis,
and segmental PD under stress with matched DE indi-
cates myocardial infarction.
Statistical analysis
The distributions of all variables were examined. In groups
categorized by the presence of delayed enhancement,
means and standard deviations were calculated for nor-
mally distributed continuous variables and compared
using t-tests. Medians and interquartile ranges were calcu-
lated for non-normally distributed continuous variables
and compared using the Kruskal-Wallis test. Counts and
proportions were calculated for categorical variables and
compared using Fisher’s exact test. Multivariable linear
regression was used to model the association of delayed
enhancement with DAS28 score. Patient characteristics
which differed by the presence of delayed enhancement
(gender, age, RA duration, use of TNF inhibitors and
Framingham 10-year hard cardiovascular disease (CVD)
event risk score) were modeled as confounders. Because of
the small sample size, hierarchical modeling was used with
a maximum of three variables simultaneously included.
The Shapiro-Wilk test confirmed normality of the
untransformed DAS28 score across distribution of the
modeled covariates. Statistical calculations were performed
using Intercooled Stata 10 (StataCorp, College Station, TX,
USA). In all tests, a two-tailed a of 0.05 was defined as the
level of statistical significance.
Results
Characteristics of the 18 participants are summarized in
Table 2. Participants were mostly female (78%) with a
mean age of 57 ± 10 years. RA duration ranged from
5 months to 16 years (median 2.7 years) with 10 partici-
pants (55.6%) categorized as having early RA (disease
duration less than three years). While most (88.9%) par-
ticipants were seropositive for rheumatoid factor (RF),
only nine (50%) had anti-cyclic citrullinated peptide
(CCP) antibodies. The mean DAS28 for the cohort was
3.96, with six participants (33.3%) falling into the low
disease activity category (DAS28 < 3.2) and six partici-
pants (33.3%) falling into the high disease activity cate-
gory (DAS28 > 5.1). TNF inhibitors were prescribed in
seven (38.9%) of the participants. The median Framing-
ham 10-year hard CVD event risk score was 2%. CV
risk factors were generally low, consistent with the study
design in which participants were deliberately selected
based on having a low risk CV risk profile.
Myocardial DE was observed in seven patients (38.9%).
Among these, enhancement was observed in the middle
layer in four patients (57.1%) (Figures 2 and 3), the sub-
endocardial layer in two (28.6%), and the subepicardial
layer in one patient (14.3%) (Figure 4). Patterns of
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(Figure 2), nodular in two patients (28.6%) (Figure 3),
and linear in one patient (14.3%) (Figure 4). Anatomi-
cally, enhancement was observed throughout the left-
ventricle, occurring in the inferolateral wall (n =2 ) ,l a t -
eral wall (n = 1), inferior wall (n = 1), anterior wall
(n = 1), and in the septum (n = 1).
None of the participants demonstrated perfusion
defects at rest. Perfusion defects under pharmacologic
stress were observed in two patients (11.1%). In one
(Figure 5), a circumferential patchy perfusion defect in
the subendocardial layer was observed and was not asso-
ciated with delayed enhancement, a pattern consistent
with microvascular coronary artery disease without
accompanying myocarditis or fibrosis. In the second
participant with a perfusion defect under stress, the
defect was non-segmental patchy in the subendocardial
layer, a pattern consistent with microvascular impair-
ment. This participant also demonstrated nodular
delayed enhancement (Figure 3). Of note, microvascular
impairment was not observed in the remaining six parti-
cipants with delayed enhancement.
Association of participant characteristics with myocardial
delayed enhancement
Participant characteristics according to the presence of any
abnormality of cardiac MRI and delayed enhancement are
summarized in Table 2. Compared to patients without
myocardial DE, patients with delayed enhancement were
more likely to be female (100% vs. 64%, respectively) and
were slightly older (mean age 62 vs. 55 years, respectively);
however, none of these differences were statistically signifi-
cant. Comparing patients with and without delayed
enhancement, there were no clinically or statistically
significant differences in current traditional cardiovascular
risk factors, including echocardiographic parameters.
Among RA parameters, median RA duration was greater,
and the proportion of patients with early disease lower, in
the group with delayed enhancement; however, these dif-
ferences were not statistically significant. Likewise, the
Figure 1 Pattern of delayed enhancement. (a) Linear enhancement in the subendocardial layer. (b) Linear enhancement in the middle layer.
(c) Linear enhancement in in the subepicardial layer. (d) Nodular enhancement in the middle layer. (e) Patchy enhancement in the middle layer.
Table 1 Interpretation based on stress and rest perfusion and delayed enhancement MRI imaging
Stress perfusion Rest
perfusion
Delayed enhacement Pathophysiological implication
Non-segmental PD (+) PD (-) DE (+) Microvascular impairment with myocarditis or fibrosis
Non-segmental PD (+) PD (-) DE (-) Microvascular impairment without myocarditis and fibrosis
Segmental PD (+) PD (-) DE (-) Macrovascular impairment
Segmental PD(+) Matched PD
(+)
Matched DE (+) Myocardial infarction
PD (-) PD (-) DE (+): Intermediate or
Subepicardial layer
Myocarditis or fibrosis without micro- and macrovascular
impairment
PD (-) PD (-) DE (+): Subendocardial layer Focal myocardial infarction (fibrosis) without micro- and
macrovascular impairment
PD (-) PD (-) DE (-) Normal
PD, perfusion defect; DE, delayed enhancement; +, present; -, absent.
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antibodies did not differ according to the presence of
delayed enhancement.
Mean DAS28 was significantly higher in the group
with delayed enhancement compared to the group with-
out by an average of 1.32 DAS28 units (4.77 vs. 3.44
units, respectively; P = 0.011). Corresponding trends to
statistical significance were noted in systemic inflamma-
tory markers, with both CRP and erythrocyte sedimenta-
tion rate (ESR) quantitatively higher in the group with
delayed enhancement. Despite higher disease activity
overall, TNF inhibitors were prescribed in only one par-
ticipant with delayed enhancement (14.3%) compared to
six without delayed enhancement (54.6%); however, this
Table 2 Participant characteristics according to presence of delayed enhancement on cardiac magnetic resonance
scanning
Characteristic * Total
n =1 8
DE present
n =7
DE absent
n =1 1
P
Female, n (%) 14 (77.8) 7 (100.0) 7 (63.6) 0.12
Age, years 57.4 ± 10.3 61.9 ± 8.6 54.6 ± 10.6 0.13
SBP, mmHg 122 ± 14 119 ± 13 124 ± 14 0.48
DBP, mmHg 76 ± 9 71 ± 7 78 ± 9 0.09
Total cholesterol, mg/dL 179 ± 19 181 ± 19 178 ± 19 0.68
HDL-C, mg/dL 52 ± 9 51 ± 9 53 ± 9 0.56
LDL-C, mg/dL 100 ± 15 105 ± 18 97 ± 13 0.33
Triglycerides, mg/dL 134 ± 21 130 ± 26 137 ± 18 0.54
Ejection fraction (echocardiogram), % 66 ± 6 67 ± 6 66 ± 6 0.71
Any perfusion defects, n (%) ** 2 (11.1) 1 (14.3) 1 (9.1) 1.00
RA duration, years; median (IQR) 2.7 (0.7 to 9.0) 8.8 (2.5 to 10.5) 1.6 (0.6 to 9) 0.26
RA duration < 3 year, n (%) 10 (55.6) 2 (20.0) 8 (80.0) 0.15
RF, n (%) 16 (88.9) 7 (100.0) 9 (81.8) 0.50
Anti-CCP, n (%) 9 (50.0) 2 (28.6) 7 (63.6) 0.34
DAS28; median (IQR) 3.96 ± 1.20 4.77 ± 0.78 3.44 ± 1.16 0.01
CRP, mg/L; median (IQR) 2.61 (1.10 to 4.22) 4.22 (3.08 to 5.28) 1.22 (0.50 to 3.40) 0.08
ESR, mm/hr; median (IQR) 47 (28 to 60) 60 (46 to 68) 39 (28 to 47) 0.09
HAQ (0-3) 0.88 (0.25 to 1.0) 1.0 (0.75 to 1.0) 0.25 (0.25 to 1.0) 0.28
Framingham risk score; median (IQR) 2.0 (0.5 to 4.0) 1.0 (0.5 to 6.0) 2.0 (1.0 to 3.0) 0.75
TNF inhibitor use, n (%) 7 (38.9) 1 (14.3) 6 (54.6) 0.15
* Characteristics are expressed as mean ± standard deviation unless otherwise noted.
** The two perfusion defects detected represented different processes. The subject with DE demonstrated a perfusion defect pattern consistent with
microvascular impairment while the subject without DE demonstrated a perfusion defect pattern consistent with macrovascular impairment.
Figure 2 Delayed enhancement of myocarditis. Delayed enhanced images showed patchy enhancement in middle layer of inferior and
lateral LV wall (arrows).
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Delayed enhancement was seen in 63.6% of patients
with negative anti-CCP-Antibody compared to 28.6% of
those with a positive anti-CCP-Antibody (prevalence
ratio 2.2), but this difference was not statistically signifi-
cant (P = 0.34).
After adjusting for confounding by gender, the asso-
ciation of myocardial delayed enhancement with DAS28
was strengthened (Table 3, Model 2), in which the
group with myocardial DE demonstrated DAS28 scores,
on average, of 1.82 units higher than the group without
myocardial DE. Additional adjustment for age, RA dura-
tion, TNF inhibitor use and Framingham 10-year hard
CVD event risk score (Table 3, Models 3 to 6) did not
modify the association of myocardial DE with DAS28
score. Myocardial DE and gender accounted for almost
half of the total variability in DAS28 (R
2 = 0.49).
Discussion
In this pilot study, we used cardiac MRI to assess myocar-
dial abnormalities in RA patients with no cardiac symp-
toms. To our knowledge, this is the first investigation to
combine both perfusion and delayed enhancement cardiac
MRI for assessing cardiac involvement in asymptomatic
patients with RA. Our preliminary data lend support for a
low prevalence of microvascular impairment in the myo-
cardium with RA patients, and a high prevalence of
delayed enhancement, suggesting myocarditis or focal
fibrosis. These findings have potential implications for
research and clinical care. For research, they suggest that
distinct pathologic processes affecting the myocardium
may be identified and tracked in RA patients using a safe,
non-invasive assessment tool, allowing for a more com-
plete understanding of the RA disease process. For clinical
care, early identification of myocardial disease may permit
Figure 3 Delayed enhancement of myocarditis. Delayed enhanced images showed nodular enhancement in middle layer of septal wall
(arrows).
Figure 4 Delayed enhancement of myocarditis. Delayed enhanced images showed linear enhancement in subepicardial layer of septal wall
(arrows).
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myocardial dysfunction on cardiovascular morbidity and
mortality in RA patients.
The clinical diagnosis of myocardial disease in RA
remains problematic. Endomyocardial biopsy (EMB) may
increase the frequency of detection; however, the sensi-
tivity of EMB may be as low as 35%, primarily because of
patchy involvement or focality of myocarditis [36]. Addi-
tionally, EMB carries a 1 in 250 risk of perforation and a
1 in 1,000 risk of death, even in experienced hands [37].
Therefore, less-invasive tools are needed to diagnose and
track cardiac abnormalities. Recent advances in cardiac
MRI enable dynamic first-pass perfusion MRI of the
entire left-ventricular myocardium with improved image
quality and higher spatial resolution compared to
SPECT. Pharmacological stress perfusion MRI has been
shown to be an accurate established method for detecting
coronary artery disease (CAD) [38]. Fenchel et al.
reported that stress examination increased the perfusion
differences of MRI between normal and ischemic myo-
cardial area compared with rest imaging [39]. Klem et al.
[40] reported that the addition of delayed enhanced MRI
to the stress-rest perfusion examination would help dis-
tinguish true perfusion defects from artifacts and
improve test reliability to the point that rapid visual
interpretation could be performed with high accuracy.
Moreover combining stress perfusion and delayed
enhanced MRI is an accurate method for characterizing
pathologic features [33,35].
Other non-invasive modalities for myocardial imaging
are available, but not as sensitive or versatile as MRI. Con-
ventional echocardiography allows for estimation of global
and regional myocardial function, but cannot distinguish
specific etiologies of dysfunction with accuracy. In addi-
tion, echocardiography requires careful standardization,
both for acquisition and interpretation, a limitation that is
considerably less for MRI. For these reasons, in our study,
echocardiography was performed solely to exclude
Figure 5 Early perfusion defect of microvascular impairment without myocardial fibrosis or myocarditis. Perfusion MRI under stress (left
figure) showed non-segmental circumferential perfusion defect (arrows). Perfusion MRI at rest (right figure) showed no defects. In this case,
delayed enhanced images showed no enhancement (not shown).
Table 3 Crude and adjusted associations of myocardial delayed enhancement with DAS28
Characteristic Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
b P b P b P b P b P b P
Delayed enhancement* 1.32 0.018 1.82 0.002 1.89 0.004 1.78 0.003 1.71 0.005 1.88 0.002
Male gender* 1.36 0.031 1.39 0.036 1.48 0.036 1.47 0.029 1.78 0.042
Age, per year** -0.01 0.74
RA duration, per year** 0.02 0.64
TNF inhibitor use* -0.36 0.49
Framingham risk score, per% -0.07 0.45
R
2( †) 0.31 0.49 0.50 0.50 0.51 0.51
* b coefficients represent the average change in the outcome (DAS28) for those with the characteristic vs. those without.
** b coefficients represent the average change in the outcome (DAS28) per 1 unit increase in the characteristic.
† R
2 is the percentage of the total variability in the outcome explained by the aggregate of the predictors in the model.
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function and not compared to the cardiac MRI studies.
SPECT has been used in two published papers in patients
with RA [16,41]. Banks et al. reported, using adenosine
stressed SPECT, that ischemic heart disease was twice as
common and more often silent in 67 RA patients com-
pared with 37 matched controls with osteoarthritis [41].
Noninvasive assessment of myocardial blood flow by ade-
nosine stressed SPECT showed reversible ischemia and
diffusely poor myocardial perfusion, suggesting myocardial
microvascular disease [16]. Although myocardial perfusion
SPECT is widely used in clinical practice and the high sen-
sitivity of SPECT has been reported, the spatial resolution
of this modality is limited and the radiation dose is proble-
matic. Furthermore, Ishida et al. [42] reported that phar-
macological stress perfusion MRI was superior to SPECT
for the assessment of myocardial ischemia in the general
population.
Non-segmental PD during pharmacological stress was
seen in 2 out of 18 patients (11%). Non-segmental PD,
not corresponding to any epicardial coronary artery dis-
tribution, is highly suggestive of microvascular impair-
ment. Coronary arteritis is seen in about 20% of RA
patients at autopsy [11]. Inflammation with edema of
the intima of the artery may lead to severe narrowing or
occlusion of its lumen, to necrosis, and angina or infarc-
tion [43]. Nevertheless, myocardial infarction secondary
to coronary arteritis is rare in patients with RA [9]. In
contrast to atherosclerosis, rheumatoid vasculitis fre-
quently involves intramyocardial arteries, indicating
microvascular impairment [9,11,44]. Raza et al. reported
reversible ischemia and diffusely poor myocardial perfu-
sion in one patient with RA using noninvasive assess-
ment of myocardial blood flow by adenosine stressed
SPECT [16]. Repeat assessment after intensive immuno-
suppression therapy revealed increased myocardial per-
fusion. Coronary angiography revealed no significant
atheroma, suggesting that myocardial microvascular dis-
ease was responsible for the ischemia. Pharmacological
stress perfusion MRI is a non-invasive tool to assess the
microvascular circulation of myocardium [21,22]. And
cardiac MRI can be repeatedly performed for the assess-
ment of therapeutic effect or follow-up examination,
because there is no radiation exposure. Our findings
would support the prospective study of the effect of RA
treatment, and associated change in joint disease activ-
ity, on myocardial perfusion defects.
Five patients (28%) had areas of DE in the middle
or subepicardial layer of the left ventricle, suggesting myo-
carditis. The detection of DE, suggesting myocarditis or
fibrosis, in 28% of our study participants is striking, parti-
cularly considering that all of the patients were asympto-
matic, had no risk factors other than RA for these
findings, and had normal conventional echocardiographic
assessments. Myocarditis is a rare but recognized form of
rheumatoid cardiac disease and is a known cause of con-
gestive heart failure [45]. Rheumatoid myocarditis can
assume a granulomatous form that is considered specific
for RA, or a nonspecific form that may also be observed in
other disorders. When present, the granulomas show a
predilection for the left ventricle and are morphologically
identical to the subcutaneous nodules of RA [9]. In con-
trast, the nonspecific inflammatory pattern involves the
collagenous interstitium of the heart, and is composed
predominantly of lymphocytes, plasma cells, and histio-
cytes [9,46]. In cardiac MRI, relatively greater gadolinium
contrast enhancement in the myocardium has been
reported in patients with active myocardial inflammation
by histopathology [47]. There may be either focal or pat-
chy diffuse enhancement of the left ventricular (LV) myo-
cardium, typically with a subepicardial or midwall
distribution [48-50]. However, isolated subendocardial dis-
tribution was not demonstrated. The LV lateral free wall is
more often involved, followed by the ventricular septum
[51]. Consistent with this, in our study, two out of five
cases with myocarditis pattern had DE in the lateral free
wall, and two had DE in the septum. In a study of indivi-
duals without RA, the extent of myocardial enhancement
was roughly correlated with LV dysfunction, and it may
decrease during healing and essentially disappear after
recovery [47].
Two patients in our study (11%) had a subendocardial
nodular DE, suggesting focal myocardial infarction. RA
patients are less likely to report symptoms of angina
and are more likely to experience unrecognized myocar-
dial infarction and sudden death [52]. Interestingly, RA
patients were more likely to be hospitalized for acute
myocardial infarction or to have experienced unrecog-
nized myocardial infarctions prior to their diagnosis of
RA [52]. In myocardial infarction, cardiac MRI typically
shows subendocardial DE [48,53]. In contrast, myocardi-
tis shows a characteristic MRI pattern of contrast
enhancement, which originates from the epicardium,
sparing the subendocardial layer [53]. Our patients had
no cardiac symptoms, no history of cardiac diseases, and
normal ECG studies; therefore these DE findings may
correspond to myocardial scarring from unrecognized
myocardial infarctions. Barbier et al. [54] reported that
49 of 259 (19.8%) randomly chosen 70-year-old subjects
had MI scars in delayed enhanced MRI. On the other
hand, only one unrecognized myocardial infarction was
found with delayed enhanced MRI in 298 subjects with
a mean age of 50 years [55]. The higher frequency of
findings suggesting myocardial scarring in our study
compared to the above published report is compelling,
but deserves study in a larger cohort of RA patients.
Interestingly, we detected a significant association
between RA disease activity and inflammation and
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dies of RA patients, those with myocarditis were noted
to have active arthritis, endocarditis, or pericarditis and
vascular changes, which strongly suggests that myocardi-
tis is associated with active forms of RA [9-11]. Longitu-
dinal follow-up is required to explore whether changes
in disease activity are associated with corresponding
changes in DE and the contribution of RA pharma-
cotherapies to dynamic changes in DE.
Our study had limitations. This was a pilot study and
the size is too small for definitive conclusions. The lack
of non-RA controls limits our ability to strongly con-
clude that our findings are unique to RA patients; how-
ever, the much higher frequency of myocardial
abnormalities observed in the present study compared
to studies conducted in non-RA patients with similar
demographic characteristics and CVD risk factors is sug-
gestive of a true disease effect. We did not perform T2-
weighted MR images, which are more reliable in differ-
entiating edema induced from acute myocarditis from
fibrosis [56]. Nonetheless our preliminary data lend sup-
port for a high prevalence of myocarditis with asympto-
matic RA patients.
Conclusions
To the best of our knowledge, our study is the largest
patient series to date to report cardiac abnormalities in
asymptomatic patients with RA using pharmacological
stress and rest perfusion, and delayed-enhanced MRI.
The detection and histological confirmation of cardiac
involvement in RA is often difficult because of a lack of
symptoms and invasive diagnostic method such as EMB.
Comprehensive cardiac MRI might be considered to be
a useful and less-invasive diagnostic tool for assessing
cardiac involvements in asymptomatic patients with RA.
Further studies of this diagnostic tool should be evalu-
ated to discuss its utility.
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